Abstract:BACKGROUND:The epidermal growth factor receptor (EGFR) is involved in the development and progression of lung cancer. Somatic EGFR mutations are predictors of response to treatment with EGFR tyrosine kinase (TK) inhibitors (TKIs) for lung cancer, especially among never smokers. EGFR mutations may occur independently of other genetic alterations.METHODS:The authors sequenced the EGFR-TK domain and the K-ras and p53 genes from lung tumor tissues from 44 never smokers and 46 smokers. A case-control study also was conducted to examine the relationship between an EGFR single nucleotide polymorphism in the TK domain and the lung cancer through a multivariate logistic regression analysis. In addition, the authors compared cell growth kinetics, EGFR-TKI sensitivity by MTT, and activation of signaling molecules by immunoblot in lung cancer cell lines with and without EGFR-TK mutations.RESULTS:EGFR-TK mutations were more frequently observed in never smokers (25%) than in smokers (2.2%) (p = 0.001). Excluding cases with a K-ras mutation, the frequency of EGFR-TK domain mutation was still significantly higher in never smokers than in smokers, 26.2% versus 4.5% (p = 0.046). EGFR-TK mutations and K-ras mutations (p = 0.015), and p53 and K-ras mutations (p = 0.015) were mutually exclusive, but p53 and EGFR-TK mutations were not (p = 1.00). During sequencing of the EGFR-TK domain in tumors, an EGFR polymorphism (G2607A) was identified. The genotype AA and AA + AG occurred at a significantly higher frequency in lung cancer cases (n = 122) when compared with controls (n = 147) (odds ratio, 3.39 and 2.67; 95% confidence interval, 1.41-8.17 and 1.17-6.08, p = 0.006 and p = 0.02, respectively). This polymorphism was found independently of EGFR-TK mutations in lung cancer cases, indicating that it does not predispose to mutations. In vitro, lung cancer cell lines with EGFR-TK mutations also did not contain K-ras mutations and displayed a lower growth rate (50%, p = 0.013) than EGFR-TK wild-type cell lines. EGFR-TK mutant cell lines were more sensitive to both gefitinib and erlotinib, although relative sensitivity to erlotinib compared with wild-type was less pronounced than for gefitinib. Cell lines with a lower growth rate also expressed higher levels of E-cadherin than faster growing cell lines.CONCLUSIONS:EGFR-TK mutation frequency is high in never-smoking lung cancer patients and is exclusive of mutation in K-ras but not p53. In addition to somatic EGFR-TK mutations that arise in lung tumors, germline variation in the EGFR-TK domain might also be associated with an increased risk of lung cancer. Somatic EGFR-TK mutations alter cell biology and response to EGFR-TKIs and may be mutation specific.

The Impact of Human EGFR Kinase Domain Mutations on Lung Tumorigenesis and in Vivo Sensitivity to EGFR-targeted Therapies.

Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer

Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.

Abstract 1574: The impact of human wild type EGFR on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

Identification Of Genetic Mutations In Human Lung Cancer By Targeted Sequencing

Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants

Targeting Microtubules Sensitizes Drug Resistant Lung Cancer Cells to Lysosomal Pathway Inhibitors.

Supplementary Figures 1 - 10 from Cetuximab Response of Lung Cancer–Derived EGF Receptor Mutants is Associated with Asymmetric Dimerization

Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer.

Functional Analysis of Receptor Tyrosine Kinase Mutations in Lung Cancer Identifies Oncogenic Extracellular Domain Mutations of Erbb2

Cellular Origins of EGFR‐Driven Lung Cancer Cells Determine Sensitivity to Therapy

Tumor Driven by Gain-of-function HER2 H878Y Mutant is Highly Sensitive to HER2 Inhibitor.

Epidermal growth factor receptor mutations in lung cancer

Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers

Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer

Abstract LT06: Understanding the Role of Mutant TP53 in Lung Cancer Using Novel Genetically Engineered Mouse Models

The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer

Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities

Perturbation of the Mutated Egfr Interactome Identifies Vulnerabilities and Resistance Mechanisms

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells

Insensitivity of Oncogenic EGFR R776L Mutation to EGFR Inhibitors in Lung Cancer